BUNGE GLOBAL SA report:
—   598 1.63% Senior Notes due 2025 597   596 3.25% Senior Notes due 2026 698   697 3.75% Senior Notes due 2027 597   596 2.75% Senior Notes due 2031 990   989 Cumulative adjustment to long-term debt from application of hedge accounting (341) (1) Other 140   155 Subtotal 4,105   5,291 Less: Current portion of long-term debt (846) (504) 
(2) Includes $207 million and $566 million of local currency borrowings in certain European, South American, and Asia-Pacific countries at a weighted average interest rate of 32.12% and 23.14% as of December 31, 2022 and December 31, 2021, respectively. 
(4) On August 23, 2022, Bunge issued a notice of redemption for all of the issued and outstanding 3.00% Senior Notes due September 25, 2022. The redemption of the 3.00% Senior Notes occurred on September 7, 2022. In connection with the redemption, for the year ended December 31, 2022, the Company recorded a $405 million payment for redemption of the notes, at par, plus accrued and unpaid interest.

ABBOTT LABORATORIES report:
• molecular diagnostics polymerase chain reaction (PCR) instrument systems, including Alinity ® m and m2000™ that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents including HIV, hepatitis, HPV, sexually transmitted infections, SARS-CoV-2 and influenza A & B, and respiratory syncytial virus (RSV); and products for oncology with the Vysis ® FISH product line of genomic-based tests; 
• rapid diagnostics lateral flow testing products in the area of infectious diseases such as SARS-CoV-2, including the BinaxNOW ® and Panbio ® rapid testing platforms, influenza, HIV, hepatitis, and tropical diseases such as malaria and dengue fever; molecular point-of-care testing for HIV, including the m-PIMA ® HIV-1/2 Viral Load Test, and for SARS-CoV-2 and influenza A & B, RSV and strep A, including the ID NOW ® rapid molecular system; cardiometabolic testing, including Afinion ® and Cholestech LDX ® platforms and tests; a toxicology business for drug and alcohol testing; and consumer self-testing; and 
• informatics and automation solutions for use in laboratories, including laboratory automation systems such as the GLP systems track™, the RALS ® point of care solution, and AlinIQ ® , a suite of informatics tools and professional services.

SALESFORCE INC report:
• the ability to unlock companies’ customer data across their business, see and understand their data with advanced analytics, make predictions with pervasive AI, automate tasks and personalize every interaction; 
• empowering developers and business users to create digital experiences with modern, low-code tools powered by leading-edge AI and configure and automate business processes to fit the needs of any business, accelerating time to value; 
We continue to expand in the growing addressable markets across all of our service offerings, providing additional opportunities for growth in our business and results. We orient our business strategy and invest for future growth by focusing on the following key priorities:
